Clinical Edge Journal Scan

Clinical Edge Journal Scan

Dapagliflozin prevents kidney function decline in T2D

Publish date: September 16, 2022

• Read More

Clinical Edge Journal Scan

New-onset AF raises the risk for CVD, CKD, and mortality in T2D

Publish date: September 16, 2022

• Read More

Clinical Edge Journal Scan

Canagliflozin reduces total CV burden in T2D patients with CKD

Publish date: September 16, 2022

• Read More

Clinical Edge Journal Scan

Commentary: Clinical Use of SGLT2 Inhibitors, GLP-1RA, and Insulin, September 2022

Publish date: September 6, 2022

• Read More

Clinical Edge Journal Scan

SGLT-2I may be preferred over DPP-4I for frail patients with T2D

Publish date: August 31, 2022

• Read More

Clinical Edge Journal Scan

Proton pump inhibitor raises the risk for T2D

Publish date: August 31, 2022

• Read More

Clinical Edge Journal Scan

Prior gestational diabetes complicates long-term macrovascular outcomes in women with T2D

Publish date: August 31, 2022

• Read More

Clinical Edge Journal Scan

T2D: High treatment persistence with dulaglutide and liraglutide

Publish date: August 31, 2022

• Read More

Clinical Edge Journal Scan

Increasing empagliflozin dose benefits T2D patients with inadequate glycemic control

Publish date: August 31, 2022

• Read More

Clinical Edge Journal Scan

T2D: Dapagliflozin consistently reduces CV and kidney disease risk irrespective of background therapy

Publish date: August 31, 2022

• Read More

Pages

• « first
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• last »